Nordic Nanovector to Present at the China Healthcare Investing & Partnering Symposium in China and Stifel Nordic Healthcare Seminar in London

12.03.2018 07:00

Oslo, Norway, 12 March 2018

Nordic Nanovector ASA (OSE: NANO) announces that the company will be presenting at the following upcoming investor conferences:

• The China Healthcare Investing & Partnering Symposium (CHIPS) in Hangzhou, China (15-17 March)

• Stifel Nordic Healthcare Seminar in London, UK (20 March)

The slides presented will be made available on Nordic Nanovector’s website ( in the Investor Relations section following the presentations.

For further information, please contact:

IR enquiries

Malene Brondberg, VP, Investor Relations and Corporate Communications

Tel/Cell: + 44 7561 431 762

Email: moc.r1521373245otcev1521373245onanc1521373245idron1521373245@ri1521373245

Media enquiries

Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: ku.oc1521373245.rdet1521373245agiti1521373245c@rot1521373245cevon1521373245ancid1521373245ron1521373245

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at

Source: Nordic Nanovector